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osting by EAbstract Background: The purpose of the study is to determine whether the pre-treatment clinical
systemic variables and optical coherence tomography (OCT) ﬁndings are associated with the sub-
sequent response to the intravitreal bevacizumab (IVB) in eyes with persistent diabetic macular
edema (DME).
Design: Prospective, interventional non-comparative case series study.
Methods: 38 Patients (45 eyes) with refractory diabetic macular edema; 16 females, 22 males with a
mean aged 57.5 year. All patients had persistent DME not responded to other forms of treatments.
Complete eye examination; best corrected visual acuity (BCVA) (represented as LOGMAR for ade-
quate statistical analysis), slit-lamp exam, intraocular pressure measurement, stereoscopic biomi-
croscopy of the macula, and morphologic patterns of diabetic macular edema demonstrated by
OCT.
All patients had intravitreal injection of 0.05 mL = 1.25 mg bevacizumab (Avastin; Genentech,
Inc., San Francisco, CA), and were followed up for 3 months. The pre and post-injection follow-
up data were analyzed by Student-t test and Mann–Whitney test for two main outcome measures;
visual acuity (LOGMAR) and central foveal thickness (CFT) changes over a period of three5720/974 4397144; fax: +974
il.com, fareed_retina@yahoo.
ity. All rights reserved. Peer-
d University.
lsevier
134 F.A. Warid Al-Laftah et al.months, and the data included demographic factors, type, duration and the control of diabetes mel-
litus (HbA1C%), grade of diabetic retinopathy, renal function (serum creatinine level), serum cho-
lesterol, blood pressure control and previous treatment by focal laser and/or intravitreal
triamcinolone injection.
Results: The LOGMAR and central foveal thickness (CRT) improved in 30/45 eyes (67%) and 32/
45 eyes (72%), respectively during a mean follow-up time of three months. The mean LOGMAR
visual acuities were 0.64 (SD ± 0.34), 0.61 (SD ± 0.31) and 0.60 (SD ± 0.32) at pre-injection, at
1 month post-injection and at 3 months post-injection, respectively; but this mean increase in vision
was statistically not signiﬁcant (P value = 0.099). The mean foveal thicknesses were 444.95 lm
(SD± 127.36), 394.95 lm (SD ± 138.03) and 378.32 lm (SD ± 112.01) at pre-injection, 1 month
post-injection and 3 months post-injection, respectively, this decrease in the foveal thickness was
statistically signiﬁcant (P value <0.001). The pre and post-injections values of the variables for dia-
betic duration, diabetic control (HbA1c) and OCT pattern of macular edema showed signiﬁcant
statistical correlations (P< 0.05) with LOGMAR only, however the values of the variables for
serum creatinine and cholesterol show statistical correlation (P< 0.05) with both LOGMAR
and CFT.
Conclusions: Chronicity and inadequate control of diabetes mellitus, nephropathy, hyperlipidemia
and presence of vitreomacular attachment (VMA) are factors associated with poor vision progress
after intravitreal bevacizumab injection.
ª 2010 King Saud University. All rights reserved.1. Introduction
Macular edema is a major cause of central vision impairment in
patients with diabetic retinopathy (Early Treatment Diabetic
Retinopathy StudyResearchGroup, 1985). Bevacizumab (Ava-
stin; Genentech, Inc., San Francisco, CA) is a full-length recom-
binant humanizedmonoclonal antibody against the receptors of
the vascular endothelial growth factor (VEGF) molecule in the
endothelial cells (Yanyali, 2007). Intravitreal bevacizumab
(IVB) has increasingly been used as a treatment for intraocular
proliferative, edematous, and neovascular diseases, such as cen-
tral retinal vein occlusion, neovascular glaucoma, exudative
age-related macular degeneration, proliferative diabetic reti-
nopathy, and recently, IVB has been frequently applied to eyes
with diabeticmacular edema leading to an increase in visual acu-
ity in some cases (Rosenfeld et al., 2005a,b; Iturralde et al.,
2006). Refractory clinically signiﬁcant diabetic macular edema
(CSME) that did not resolve with several sittings of focal laser
photocoagulation (FLP) and intravitreal injections may result
in an increased risk of vision loss. Systemic factors, such as poor
glycemic, cholesterol, blood pressure and control, may be con-
tributing to the persistence of the macular edema. Up to date
there is no existing published study assessing the correlation be-
tween bevacizumab (Avastin) treatment response of refractory
CSME and co-morbidity systemic factors. The purpose of our
study is to determine whether the pre-treatment systemic and
ocular variables are associated with the subsequent response
to the IVB in eyes with persistent DME.2. Patients and methods
This is a prospective, consecutive and non-comparative case
series of 38 patients (45 eyes) 16 females, 22 males, the mean
age was 57.5 years.
Inclusion criteria include refractory diabetic macular edema
which does not responded to previous treatments as focal laser
and/or intravitreal triamcinolone injection, CFT on serialOCT showed reduction not more than 100 lm, and also visual
acuity increased by not more than 0.2 LOGMAR (2 lines in
snellen chart) from previous treatments, the ocular media in all
patients were clear enough to document DME by OCT, and no
macular ischemia by Fluorescein Angiography (FFA). FFA
conﬁrmed no signiﬁcant ischemic changes in the macula of
(43 eyes) 36 patients (FFA was not done (contraindicated) in
2 eyes/2 patients).
Exclusion criteria include treated DME within 3 months
prior to IVB injection, previous vitrectomy and/or gas injec-
tion and vitreous hemorrhage.
Every patient had been well-informed about the quality of
the treatment and acknowledged comprehensively about risk/
beneﬁt ratio of IVB injection and an informed consent was ob-
tained from each patient.
The injection procedure for all patients was performed in
the operating theatre so as to minimize the risk of intraocular
infection. Sterilization accomplished by topical 5% povidone-
iodine, 0.05 mL = 1.25 mg of IVB injected into mid-vitreous
by 30 gauge needle, 3–4 mm posterior to inferotemporal lim-
bus, postoperative topical antibiotics instilled for 5 days, and
all patients followed up for 12 weeks.
At each visit (pre and post injection) patients underwent
complete eye examination; BCVA (represented as LOGMAR
for adequate statistical analysis), slit-lamp exam, intraocular
pressure measurement, stereoscopic biomicroscopy of the mac-
ula, and morphologic patterns of (DME) demonstrated by
(OCT) Kim et al., 2006. OCT assessment for central foveal
thickness (CFT) changes and vitreomacular attachment
(VMA). The baseline pre and post-injection follow-up data
were analyzed and compared for two main outcome measures
VA (LOGMAR) and CFT changes over the period of three
months. Data studied and analyzed for variables for demo-
graphic factors, type and duration of DM, the control of dia-
betes (HbA1c%), grade of diabetic retinopathy, serum
creatinine level, serum cholesterol, blood pressure, previous
treatments (not <6 months) either by focal laser and /or intra-
vitreal triamcinolone injection.
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The correlations between the Pre and Post injection variables
were studied by using Student-t test and Mann–Whitney test,
The level P< 0.05 was considered as the cut-off value for
the signiﬁcance.Figure 1 VA (LOGMAR) over 3 months. Improved = reduc-







Figure 2 OCT changes over 3 months. Improved = reduction in
CFT by P100 lm. Total number = 45 eyes of 38 patients.
Table 1 (VA) LOGMAR correlation with variables.
Factor LOGM
Impro
HbA1c 67% 7 (47%
>7% 8 (53%
Duration of DM <10 years 6 (60%
P10 years 5 (40%
DM grade NPDR 10 (67
PDR 5 (33%
Hypertension No HTN or controlled to age 7 (47%
Uncontrolled to age 8 (53%
Cholesterol 65.17 mmol 12 (80
>5.17 mmol 3 (20%
Serum creatinine <62 mmol 9 (60%
62–124 mmol 6 (40%
>124 mmol 0
OCT pattern Diﬀuse 8 (53%
Diﬀuse + CME 7 (47%
Diﬀuse + CME+ VMA 0
Focal laser No 0
One 13 (87
PTwo 2 (13%
IVTA No 8 (53.
Yes 7 (45.
Total number = 45 eyes of 38 patients.
ImprovedP 0.2 reduction in LOGMAR, IVTA= intravitreal triamcino4. Results
Forty ﬁve eyes of 38 patients who completed 3 months of fol-
low-up were included for analysis. 31 patients had injection in
one eye, and 7 patients had injection in both eyes at an interval
of 1–2 weeks (mean: 1.4 weeks).
Demographic and diabetes characteristics.
Gender: (M/F) 22/16
Age: 57.5 SD: 14
Diabetes onset age: 48 SD± 10 years






loThe visual acuity changes presented in LOGMAR and the
macular anatomical changes by OCT indicated by
CFT = central foveal thickness.The visual acuity improved
(P0.2 LOGMAR) in 30/45 eyes (67%) Fig. 1 and CRT re-
duced by (P100 lm) in 32/45 eyes (72%) Fig. 2.
The mean LOGMAR visual acuities were 0.64
(SD ± 0.34), 0.61 (SD ± 0.31) and 0.60 (SD ± 0.32) at pre-
injection, at 1 month post-injection and at 3 months post-injec-
tion, respectively; but this mean increase in vision was statisti-
cally not signiﬁcant (P value = 0.099). The mean foveal
thicknesses were 444.95 lm (SD± 127.36), 394.95 lm
(SD± 138.03) and 378.32 lm (SD± 112.01) at pre-injection,
1 month post-injection and 3 months post-injection, respec-
tively, this decrease in the foveal thickness was statistically sig-
niﬁcant (P value <0.001).
All eyes had DME which was refractory to treatment with
conventional macular laser photocoagulation and or intravi-
treal triamcinolone injection which was carried outP6 months
prior to the IVB injection, 23 eyes had non-proliferative stage
of diabetic retinopathy and 22 eyes had proliferative stage ofAR Total P value
ed Not improved
) 3 (10%) 10 (22%) 0.009
) 27 (90%) 35 (78%)
) 22 (73%) 28 (65%) 0.01
) 12 (27%) 17 (35%)
) 13 (43%) 23 (51%) 0.14
) 17 (57%) 22 (49%)
) 13 (43%) 20 (44.5%) 0.30
) 17 (57%) 25 (55.5%)
) 20 (67%) 32 (71%) 0.04
) 10 (33%) 13 (29%)
) 6 (20%) 15 (33.33%) 0.04
) 21 (70%) 27 (60%)
3 (10%) 3 (6.66%)
) 7 (23.3%) 15 (33.3%) 0.009
) 14 (46.7%) 21 (46.7%)
9 (30%) 9 (20%)
2 (7%) 2 (4.5%) 0.2
) 20 (67%) 33 (73.3%)
) 8 (26%) 10 (22.2%)
) 22 (73.3%) 30 (66.7%) 0.496
) 8 (26.7%) 15 (33.3%)
ne.
Table 2 Central foveal thickness (CFT) correlation with variables.
Variable CFT Total P value
Improved Not improved
HbA1c 67% 5 (15%) 5 (42%) 10 (22%) 0.1
>7% 28 (85%) 7 (58%) 35 (78%)
Duration of DM <10 years 20 (60.6%) 7 (58%) 30 (67%) 0.2
P10 years 13 (39.4%) 5 (42%) 15 (33%)
DM grade NPDR 16 (49%) 7 (58%) 23 (51%) 0.5
PDR 17 (51%) 5 (42%) 22 (59%)
Hypertension No HTN/controlled to age 12 (36%) 8 (67%) 20 (45%) 0.07
Uncontrolled to age 21 (64%) 4 (33%) 25 (55%)
Cholesterol 65.17 mmol 26 (79%) 6 (50%) 32 (71%) 0.045
>5.17 mmol 7 (21%) 6 (50%) 13 (29%
Serum creatinine <62 mmol 11 (33.3) 4 (33.3) 15 (33.3) 0.04
62–124 mmol 20 (60.6) 7 (58.3) 27 (60.0)
>124 mmol 2 (6.1) 1 (8.3) 3 (6.7)
OCT pattern Diﬀuse 10 (30.3%) 5 (42%) 15 (33%) 0.47
Diﬀuse + CME 15 (45.5%) 6 (50%) 21 (47%)
Diﬀuse + CME+ VMA 8 (24.2) 1 (8%) 9 (20%)
Focal laser No 2 (6%) 0 2 (4%) 0.1
One 25 (76%) 8 (67%) 33 (73%)
PTwo 6 (18%) 4 (33%) 10 (23%)
IVTA No 23 (70%) 7 (58%) 30 (67%) 0.496
Yes 10 (30%) 5 (42%) 15 (33%)
Total number = 45 eyes of 38 patients.
Improved = reduction in CFT byP 100 lm, IVTA= intravitreal triamcinolone.
Table 3 Clinical variables correlated with statistical changes
in (LOGMAR and CFT).
Variable LOGMAR CFT
Chronicity of DM +VE= P 0.01 VE= P 0.2
DM control (Hb A1C) +VE= P 0.009 VE= P 0.1
OCT type of DME +VE= P 0.009 VE= P 0.47
S. Creatinine +VE= P 0.04 +VE= P 0.04
S. Cholesterol +VE= P 0.04 +VE= P 0.045
+VE= signiﬁcant statistical correlation.
VE= no signiﬁcant statistical correlation.
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and other 37 (44 eyes) were type II, all eyes with proliferative
diabetic retinopathy were stabilized by the panretinal photoco-
agulation performed at leastP6 months earlier, the post-injec-
tion outcome (LOGMAR and CFT) was different in
relationship with each studied variable and showed diverse sta-
tistical correlation (Tables 1 and 2).
Five out of nine studied variables proved to be statistically
correlated (P< 0.05) with post-injection VA (LOGMAR);
duration of diabetes, Diabetic control (HbA1C%), pattern of
macular edema, creatinine and cholesterol, however only two
variables showed signiﬁcant correlation with CFT (P< 0.05);
serum cholesterol and creatinine (Table 3).
5. Discussion
Diabetes mellitus is a chronic disease affecting the metabolism
of the carbohydrates which damage microvasculature in kid-
neys, blood vessels, peripheral nerves and eyes, causing com-
plicated disorders which subsequently produce more
complications such as retinopathy and triggering the breakof the blood–retina barrier and increase permeability in dia-
betic retinopathy (Wang et al., 1993).
Control of diabetes can be assessed by several methods, and
the most practical sensitive one is measurement of HBA1c%le-
vel, and a reduction in progression and severity of retinopathy
was seen when HbA1C is reduced to <7% (The Diabetes Con-
trol and Complications Trial Research Group, 1993). We used
HbA1c level 7% as an indication for diabetic control, 2/3rd of
our patients were found to be uncontrolled diabetics (HbA1c
>7%) and this group of patients were having a less chance
for VA improvement after IVB (P value = 0.009), and on
the other hand, the CFT values in this group of patients was
showing changes not >100 lm after IVBand these statistically
not signiﬁcant (P value = 0.1), however the ﬁndings of other
studies conﬁrmed that patients with HbA1c of 68 had a de-
crease in foveal thickness (Lai et al., 2008).
Several studies have proven that elevated serum lipid levels
maybe an additional risk factor for CSME (Chew et al., 1996;
Ferris et al., 1996; Roy and Klein, 2001; Klein et al., 1991), and
we found that hypercholestremic patients >5.17 mmol are
more vulnerable for having poor post-injection progress both
in VA and CFT (P value = 0.04, 0.045, respectively).
High systolic blood pressure increases prevalence and sever-
ity of retinopathy in diabetes (Calhoun et al., 2008; Cignarelli
et al., 1992; Stratton et al., 2001) It also has been proven that
antihypertensive medication (Furosemide) may be beneﬁcial in
treating macular edema in hypertensive diabetic patients
(Ciardella et al., 2007). In accordance with previous studies
(Cignarelli et al., 1992; Stratton et al., 2001), our case series
conﬁrm that those who were having uncontrolled blood pres-
sure (>50% patients) would most likely to have persistence
of their macular edema after IVB, and CFT either worsen or
changed less than100 Microns (P value = 0.07), and also no
statistically signiﬁcant visual improvement (P value = 0.3).
Pretreatment clinical variables associated with the response to intravitreal bevacizumab 137Our ﬁndings were in agreement with the well-established
statement that the severity of retinopathy and maculopathy
are strongly associated with the duration of diabetes, (Early
Treatment Diabetic Retinopathy Study Research Group,
1985; Liu et al., 2002) and in our cases, the shorter diabetes
duration (<10 years) were having the better the visual acuity
after IVB (P value = 0.01), Table 3.
The poor responders to IVB in our patients, were having re-
nal dysfunction (creatinine >124 mmol) and it has been re-
ported that diabetic macular edema is signiﬁcantly resolved
after hemodialysis (Akduman et al., 2008), we found both visual
acuity and macular thickness were not optimized after IVB in
those having high serum creatinine (P value = 0.004), Table 3.
The vast majority of authors use OCT as the best indicator
of therapeutic beneﬁt. The amount of information given by
OCT demonstrates that macular edema is a complex clinical
entity with various morphology (Yanyali, 2007), and DME
exhibits ﬁve different morphologic patterns on OCT (Kim
et al., 2006; Panozzo et al., 2004); diffuse retinal thickening,
cystoid macular edema, vitreomacular attachment (VMA), ser-
ous retinal detachment, and traction retinal detachment .Three
patterns have only been shown in our patients; diffuse pattern
with or without cystoids changes and VMA. We noticed a rel-
atively good improvement in post-injection VA particularly for
those with diffuse pattern without cystoids or VMA compo-
nent (P value = 0.02), but no comparable achievement noticed
in the post-injection CFT (P value = 0.47).
According to the history of (Focal Laser Photocoagulation)
FLP, we classiﬁed the patients into 3 groups; no FLP, one FLP
and two FLP, however the majority of our patients had one
FLP and 25/33 (76%) of this group showed ﬂattening of mac-
ula by OCT (positive anatomical response), and 20/33 (61%)
showed reduction in vision (negative functional response)
post-injection, and this result is supported by ﬁnding of Vivi-
enne C. Greenstein et al. who suggest that focal treatment pro-
duces changes in retinal function (Vivienne, 2000).
The IVB injection outcome was not signiﬁcantly different
whether the patient in the non-proliferative stage or regressed
proliferative stage (all patients had completed PRP).
In our cases;15 (33%) have history of IVTA injection at
least 6 months earlier to IVB and 30 (67%) havenot; and there
was no signiﬁcant difference between the two groups and this
could be due to the beneﬁcial effects of IVTA are transient and
may last up to 6 months (Beer et al., 2003; Jonas et al., 2004).
The limitations of our study were short term follow up,
uncontrolled study and a single reading for systemic variables
is not a sufﬁcient indicator for systemic control (i.e. need serial
measurements).
6. Conclusion
More chronicity and poorly controlled diabetes mellitus,
nephropathy, hyperlipidemia and presence of VMA or macu-
lar cysts are associated with a poor response of DME after
IVB injection.
7. Recommendations
It is essential to keep good control of Diabetes and Systemic
factors to optimize the response for IVB injection in DME.
These short-term results encourage further prospective studywith the consideration of serial monitoring for both diabetes
and the co-morbidity systemic risk factors over a longer
period.Acknowledgments
The authors thank Dr. Abdulbari Benar, for his assistance
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